Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 330

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 330
---
 operational and financial risks, including:

| • |     | increased near-term and long-term expenditures; |

| • |     | exposure to unknown liabilities; |

- 230 -

| • |     | higher than expected acquisition, disposition or integration costs; |

| • |     | incurrence of substantial debt or dilutive issuances of equity securities to fund future operations; |

| • |     | write-downs of assets or incurrence of non-recurring, impairment or other 
 charges;                                                                  |

| • |     | difficulty and cost in combining the operations and personnel of any acquired business with our operations and 
 personnel;                                                                                                     |

| • |     | impairment of relationships with key suppliers or customers of any acquired business due to changes in management 
 and ownership;                                                                                                    |

| • |     | inability to retain key employees of our company or any acquired business; and |

| • |     | possibility of future litigation. |

Any of the foregoing risks could have a material adverse effect on our business, financial condition and prospects. Our board of directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities. There can be no assurance that a strategic transaction, such as the Divestiture, will be completed and, whether or not such strategic transaction is completed, our board of directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such decision and, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution and liquidation, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations and the timing of any such resolution is uncertain. In addition, we may be subject to litigation or other claims related to a dissolution and liquidation. If a dissolution and liquidation were pursued, our board of directors, in consultation with our advisors, would need to evaluate these matters